Lexeo Therapeutics, Inc./$LXEO
1D1W1MYTD1Y5YMAX
Capital at risk
About Lexeo Therapeutics, Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.
- Ticker
- $LXEO
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 63
- Headquarters
- New York, United States
- Website
- www.lexeotx.com
LXEO Metrics
BasicAdvanced
$349M
-
-$1.15
1.47
-
Price and volume
Market cap
$349M
Beta
1.47
52-week high
$10.99
52-week low
$3.99
Average daily volume
794K
Financial strength
Current ratio
13.887
Quick ratio
13.574
Long term debt to equity
1.763
Total debt to equity
2.898
Interest coverage (TTM)
-1,302.97%
Profitability
EBITDA (TTM)
-94.504
Management effectiveness
Return on assets (TTM)
-27.59%
Return on equity (TTM)
-46.76%
Valuation
Price to book
1.42
Price to tangible book (TTM)
1.42
Price to free cash flow (TTM)
-3.65
Free cash flow yield (TTM)
-27.40%
Free cash flow per share (TTM)
-1.165
Growth
Earnings per share change (TTM)
-64.15%
3-year earnings per share growth (CAGR)
-69.17%
Bulls say / Bears say
Lexeo finalized its SUNRISE-FA 2 pivotal trial protocol and statistical analysis plan for LX2006, aligning with FDA feedback to initiate enrollment by end-June 2026 and targeting topline data in H2 2027, thereby de-risking its regulatory pathway. (Reuters)
A corporate deck released in March 2026 highlighted interim Phase I/II efficacy and safety results for LX2006, reporting mean LVMI reductions of 18% at six months and 23% at 12 months with no Grade 3 treatment-related serious adverse events, exceeding FDA-aligned targets. (Reuters)
Lexeo is showcasing its pipeline breadth and manufacturing readiness with presentations at the ASGCT Annual Meeting in May 2026, covering updated LX2006 data, preclinical TNNI3 cardiomyopathy work, and AAV manufacturing comparability, underscoring advancing technical progress. (Reuters)
Lexeo's FY25 net loss widened to USD 100 million despite a year-end cash position of USD 250 million, indicating a high cash burn rate that may require additional capital before commercialization. (Reuters)
Even after finalizing its pivotal trial design, Lexeo’s shares remain down approximately 50% year-to-date, reflecting persistent investor skepticism about its near-term value drivers. (Reuters)
The SUNRISE-FA 2 trial’s open-label design without a placebo or sham procedure, as advised by the FDA, could introduce bias and limit the interpretability of efficacy results, potentially complicating regulatory review. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 24 Aug 2026.
Upcoming events
No upcoming events
LXEO News
AllArticlesVideos
Funds containing LXEO
AllUSDGBPEUR
Fund name | Fund size | $LXEO weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.02% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.02% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.